Navigation Links
Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Date:9/10/2012

SUNNYVALE, Calif. and SEATTLE, Sept. 10, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today presented positive data from its randomized, double-blind Phase 2a clinical study of CLP1001.  In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo.   

Data from the Phase 2a study were presented by Barry M. Massie, M.D., Professor, University of California, San Francisco, President of the Heart Failure Society of America and member of Sorbent's Medical Advisory Board, during the Late-Breaking News Symposium at the Heart Failure Society of America 16th Annual Scientific Meeting in Seattle, Washington.  

"The results of this clinical study suggest that CLP1001 may provide important benefits in addressing the signs and symptoms of heart failure," said Dr. Massie.  "Specifically, the reduction of dyspnea and improved physical functionality among patients dosed with CLP1001 are associated with a better quality of life in heart failure patients already on standard guideline recommended medications."

"Heart failure symptoms are generally debilitating – in spite of currently available therapies.  The positive findings from our Phase 2a clinical trial indicate that CLP1001 may improve patient outcomes," said Howard C. Dittrich, M.D., F.A.C.C., Sorbent's Chief Medical Officer.  "We look forward to working closely with the clinical community on additional clinical studies where we plan to measure the effects of CLP10001 on the physical functionality and overall quality of life of heart failure patients when administered in combination with standard medications for heart failure."

About the Phase 2a Study and Reported Clinical Results

The double-blind, randomized, parallel, placebo-controlled study examined the effe
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
3. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
4. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
(Date:10/22/2014)... RPh, of Vernak Farms Pharmacy in Skaneateles, ... Roentsch Scholarship by the Professional Compounding Centers of America ... during PCCA,s International Seminar, held October 8-10, ... pharmacist and PCCA member who embodies the innovative and ... pharmacist in the compounding community. George ...
(Date:10/22/2014)... Oct. 22, 2014 Moms are ready to ... for themselves and their kids, according to the results ... & Fitness Go Mobile for Moms, the latest installment ... the number 1 pregnancy and parenting web and mobile ... percent of moms surveyed say they can,t think of ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Not getting ... of ulcerative colitis, a new study suggests. Those ... to eight hours per night may be more prone ... the intestines, researchers report. The study authors concluded that ... be considered among patients with inflammatory bowel diseases. ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... What: In recognition of November ... LOJN ) has hosted an educational podcast ( ... Alzheimer,s including: , The rising incidence of Alzheimer,s ... people with Alzheimer,s and their caregivers Risks such ...
... Inc. (Nasdaq: SLTM ), a global leader in the ... ended September 30, 2009. Revenue for the quarter was in-line ... for the third quarter was $17.8 million, an increase of ... quarter 2008 reflecting increased revenue as a result of the ...
... high rate of premature births , TUESDAY, Nov. ... mortality, the United States lags dismally behind most other ... of babies delivered prematurely, according to a new government ... the world in infant mortality," said Marian F. MacDorman, ...
... stage small cell lung cancer(LSCL) with a combination of ... opening the door to larger scale investigation, according to ... Anderson Cancer Center. The Phase II study was ... the annual meeting of the American Society for Radiation ...
... ... started posting surgical videos as part of a new section on its website called ... chest syndrome in pediatric patients. As part the new portion of Baptist,s website to ... of video. , ...
... , SHENZHEN, China, Nov. 3 /PRNewswire-Asia-FirstCall/ ... Nepstar" or the "Company"), the largest,drugstore chain in China based ... has entered into a strategic cooperation agreement,with ATMU (China) Technology ... ATM operators in China, to install ATMs in Nepstar stores. ...
Cached Medicine News:Health News:November is National Alzheimer's Awareness Month 2Health News:Solta Medical Reports Third Quarter 2009 Results 2Health News:Solta Medical Reports Third Quarter 2009 Results 3Health News:Solta Medical Reports Third Quarter 2009 Results 4Health News:Solta Medical Reports Third Quarter 2009 Results 5Health News:Solta Medical Reports Third Quarter 2009 Results 6Health News:Solta Medical Reports Third Quarter 2009 Results 7Health News:Solta Medical Reports Third Quarter 2009 Results 8Health News:Solta Medical Reports Third Quarter 2009 Results 9Health News:Solta Medical Reports Third Quarter 2009 Results 10Health News:CDC Finds U.S. 30th in Infant Mortality 2Health News:CDC Finds U.S. 30th in Infant Mortality 3Health News:Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer 2Health News:Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer 3Health News:New Video Post Shows Minimally Invasive Procedure To Correct Sunken Chest Syndrome 2Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 2Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 3
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: